Crossing the Blood–Brain Barrier: Study on Adipose-Derived Stem Cells as Carriers for Pro-Apoptotic Oncolytic Myxoma Virus in the Treatment of Murine Glioblastoma Background and Objective Glioblastoma (GBM) is among the most invasive and aggressive brain tumors, characterized by high recurrence rates and poor prognosis. Despite multimodal intervent...
Inhibitory Fcγ Receptor Deletion Enhances CD8 T Cell Stemness, Increasing Anti-PD-1 Therapy Responsiveness in Glioblastoma Background and Objectives of the Study Glioblastoma (GBM) is an aggressive central nervous system tumor with poor prognosis, and the median survival of patients is only 14.6 months. Despite the significant efficacy of immune ch...
Paper Report: The Role of MDH2 in Epitranscriptomic Metabolic Regulation of Glioblastoma Stem Cells Introduction and Background Glioblastoma (GBM) is the most common and lethal primary brain malignant tumor in adults. GBM cells utilize a metabolic pathway known as the Warburg effect, which involves increased glucose uptake through aerobic glycolysi...
Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...
Brain Glioblastoma PDGFRA, KIT and KDR Gene Amplification: Heterogeneity and Its Clinical Significance Academic Background Glioblastoma (GBM) is the most common malignant tumor of the central nervous system, with its heterogeneity posing significant challenges in treatment. GBM exhibits cellular genetic and phenotypic diversity not only between dif...
Single-Cell Atlas Reveals Immunosuppressive Microenvironment and Treg Cell Distribution in Recurrent Glioblastoma Glioblastoma is the most aggressive brain tumor, with a very high recurrence rate and poor prognosis. Although many studies have explored the tumor microenvironment of this disease, the understanding of the immune microenvironment in re...
Comprehensive Analysis of Leptomeningeal Metastasis in IDH Wild-Type Glioblastoma In this article published in the journal “Neuro-Oncology,” the research team starting in 2024 delves into the incidence, risk factors, and prognosis of leptomeningeal metastases (LM) in patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma. This study wa...
Study on the Extent of Resection Threshold in Different Molecular Subtypes of Newly Diagnosed IDH-wildtype Glioblastoma Introduction Glioblastoma (GBM) is the most common malignant brain tumor in adults. Although surgical resection, radiotherapy, and chemotherapy are the current standard treatment regimens, the prognosis of GBM remains poor, with a...
Immunotherapy Drives Mesenchymal Transition and Tumor Microenvironment Immune Response in Glioblastoma Introduction Glioblastoma is a highly malignant brain tumor with no curative treatment currently available. Although immunotherapy has shown efficacy in other cancer types, the response in glioblastoma patients is limited. Investigating the effect...
The human genome-encoded triggering receptor expressed on myeloid cells 2 (TREM2) was initially thought to play a role primarily in the central nervous system, participating in the functional regulation of microglia. In recent years, researchers have found that TREM2 is also expressed in peripheral tumors and may promote tumor progression. However,...